Pharma Focus Asia
Klöckner Pentaplast - Pentapharm® alfoil® films

Sandoz Discovered First-of-its-kind Tyruko® Biosimilar for Multiple Sclerosis

Sandoz has introduced first-of-its-kind Tyruko® (natalizumab-sztn) biosimilar designed specifically for the treatment of relapsing forms of multiple sclerosis. 

Tyruko is the first and only FDA-approved biosimilar for relapsing forms of multiple sclerosis. Tyruko has been developed to exhibit a remarkably close resemblance to the reference medication, which happens to be a well-established and highly efficient disease-modifying treatment for relapsing forms of multiple sclerosis

This reference medicine is an anti-α4 integrin monoclonal antibody, recognised for its effectiveness in managing the condition.

In the United States, Tyruko has received approval for use as a standalone therapy to treat various forms of multiple sclerosis, encompassing clinically isolated syndrome (CIS), relapsing-remitting MS (RRMS), and active secondary progressive disease. Furthermore, it is also indicated for the treatment of Crohn’s disease in adult patients. 

Tyruko closely mirrors the reference medicine in terms of its intravenous (IV) dosage form, route of administration, dosing regimen, and presentation.

Biosimilars are an important treatment option as they have no clinically meaningful differences from their reference medicines. Prescribing biosimilars enhances access to affordable medications, improves adherence, and contributes to controlling healthcare costs.

magazine-slider-imageBIOVIA from Molecule to MedicineMFA + MMA 2024CPHI China || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopCPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinRehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference3rd World ADC Asia 2024LogiPharma Asia 2024